EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Trial · NCT02635386
Adverse events65
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 65
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Yeast infection or urinary tract infection | Renal and urinary disorders | Exenatide Once Weekly (EQW ) | 0 | 23 | |
| other | Yeast infection or urinary tract infection | Renal and urinary disorders | Dapagliflozin (DAPA) | 6 | 23 | |
| other | Yeast infection or urinary tract infection | Renal and urinary disorders | EQW Plus DAPA | 7 | 22 | |
| other | Yeast infection or urinary tract infection | Renal and urinary disorders | Dapagliflozin Plus Glucophage (MET ER) | 7 | 26 | |
| other | Yeast infection or urinary tract infection | Renal and urinary disorders | Phentermine /Topiramate (PHEN/ TPM) ER | 0 | 25 | |
| other | Nausea and upset stomach | Gastrointestinal disorders | Exenatide Once Weekly (EQW ) | 5 | 23 | |
| other | Nausea and upset stomach | Gastrointestinal disorders | Dapagliflozin (DAPA) | 0 | 23 | |
| other | Nausea and upset stomach | Gastrointestinal disorders | EQW Plus DAPA | 0 | 22 | |
| other | Nausea and upset stomach | Gastrointestinal disorders | Dapagliflozin Plus Glucophage (MET ER) | 6 | 26 | |
| other | Nausea and upset stomach | Gastrointestinal disorders | Phentermine /Topiramate (PHEN/ TPM) ER | 3 | 25 | |
| other | Injection site reaction | Skin and subcutaneous tissue disorders | Exenatide Once Weekly (EQW ) | 5 | 23 | |
| other | Injection site reaction | Skin and subcutaneous tissue disorders | Dapagliflozin (DAPA) | 0 | 23 | |
| other | Injection site reaction | Skin and subcutaneous tissue disorders | EQW Plus DAPA | 4 | 22 | |
| other | Injection site reaction | Skin and subcutaneous tissue disorders | Dapagliflozin Plus Glucophage (MET ER) | 0 | 26 | |
| other | Injection site reaction | Skin and subcutaneous tissue disorders | Phentermine /Topiramate (PHEN/ TPM) ER | 0 | 25 | |
| other | Vaginal irritation | Reproductive system and breast disorders | Exenatide Once Weekly (EQW ) | 0 | 23 | |
| other | Vaginal irritation | Reproductive system and breast disorders | Dapagliflozin (DAPA) | 1 | 23 | |
| other | Vaginal irritation | Reproductive system and breast disorders | EQW Plus DAPA | 1 | 22 | |
| other | Vaginal irritation | Reproductive system and breast disorders | Dapagliflozin Plus Glucophage (MET ER) | 0 | 26 | |
| other | Vaginal irritation | Reproductive system and breast disorders | Phentermine /Topiramate (PHEN/ TPM) ER | 0 | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02635386/events